Metabolic/Obesity Phase 1 Deal Benchmarks — Ex-US (2026)
Median upfront of $103M with total deal values reaching $1.2B in Ex-US territory.
Median Upfront
$103M
Total Deal Value
$807M
Royalty Range
7.3%–13.7%
Territory Multiplier
0.45x
Understanding Metabolic/Obesity Deal Benchmarks at Phase 1
Phase 1 Metabolic/Obesity licensing deals in Ex-US territory command a median upfront payment of $103M, with values ranging from $48M at the low end to $158M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $444M to $1.2B, with a median of $807M. Royalty rates for metabolic/obesity assets at this stage typically fall between 7.3% and 13.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $48M | $103M | $158M |
| Total Deal Value | $444M | $807M | $1.2B |
| Royalty Rate | 7.3% | — | 13.7% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2021 | Xeris Pharmaceuticals | Tetris Pharma | $0M | $71M | reformulation |
See All Comparable Deals
View 1 comparable Metabolic/Obesity transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Metabolic/Obesity deals in Ex-US territory?
How does Ex-US territory affect Metabolic/Obesity deal value?
What royalty rates are typical for Phase 1 Metabolic/Obesity licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$35M upfront
Metabolic/Obesity · Preclinical · Ex-US
$265M upfront
Metabolic/Obesity · Phase 2 · Ex-US
$554M upfront
Metabolic/Obesity · Phase 3 · Ex-US
$1.6B upfront
Metabolic/Obesity · Approved · Ex-US
$40M upfront
Oncology · Phase 1 · Ex-US
$34M upfront
Neurology/CNS · Phase 1 · Ex-US
$74M upfront
Immunology · Phase 1 · Ex-US
$229M upfront
Metabolic/Obesity · Phase 1 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Metabolic/Obesity Phase 1 Deal Benchmarks — Ex-US (2026). Retrieved from https://solidus.ambrosiaventures.co/data/metabolic-phase-1-deals-ex-us
<a href="https://solidus.ambrosiaventures.co/data/metabolic-phase-1-deals-ex-us">Metabolic/Obesity Phase 1 Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=metabolic&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.